从印度旁遮普邦鉴定出一种新型丙型肝炎病毒基因型:将丙型肝炎病毒分类扩展至8种基因型
对标准商业基因分型方法未能确定基因型的血浆样本进行HCV全基因组测序和系统发育分析,4例原被LiPA或Abbott RealTime PCR归类为GT5的患者被鉴定感染新型HCV GT8,其与已确立的HCV亚型核苷酸序列差异超过30%。4例患者均来自印度旁遮普邦、现居加拿大且流行病学无关联,尽管基线存在耐药相关替换,所有患者均获得持续病毒学应答。
要点
- 新型HCV基因型GT8与已知GT1-7遗传学不同,与已确立HCV亚型的核苷酸序列差异超过30%。
- 4例患者原被LiPA或Abbott RealTime PCR归类为GT5,全基因组测序鉴定为GT8。
- 4例GT8病毒均携带基线耐药相关替换(NS3:V36L、Q80K/R;NS5A:Q30S、Y93S),所有患者均获得持续病毒学应答。
核心结论
- 新型HCV基因型GT8的发现证实这一新鉴定的谱系在人群中传播。
研究设计与样本
- 对标准商业基因分型方法未能确定基因型的血浆样本进行HCV全基因组测序,并通过系统发育分析确定基因型。
主要发现
- 4例患者原被LiPA或Abbott RealTime聚合酶链反应检测归类为GT5,经全基因组测序鉴定为感染新型HCV基因型GT8。
- 新型HCV GT8与先前鉴定的HCV GT1-7遗传学不同,与已确立的HCV亚型的核苷酸序列差异超过30%。
- 4例患者均原籍印度旁遮普邦、现居加拿大,且流行病学无关联。
- 4例患者的GT8病毒均存在基线耐药相关替换(NS3:V36L、Q80K/R;NS5A:Q30S、Y93S),但所有患者均获得持续病毒学应答。
关键数值与推荐
- 2例接受索磷布韦/维帕他韦/伏西瑞韦治疗8周。
- 1例接受索磷布韦/来迪派韦联合利巴韦林治疗24周。
- 1例接受索磷布韦联合达拉他韦治疗12周。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis C virus (HCV) exhibits great genetic diversity and is classified into 7 genotypes (GTs), with varied geographic prevalence. Until the recent development of pangenotypic direct-acting antiviral regimens, the determination of HCV GT was necessary to inform optimal treatment. METHODS: Plasma samples with unresolved GT using standard commercial genotyping methods were subjected to HCV full-genome sequencing, and phylogenetic analysis was performed to assign GT. RESULTS: Four patients, previously classified as GT5 by LiPA or Abbott RealTime polymerase chain reaction assays, were identified as infected with a novel HCV GT. This novel HCV GT, GT8, is genetically distinct from previously identified HCV GT1-7 with >30% nucleotide sequence divergence to the established HCV subtypes. All 4 patients were originally from Punjab, India, but now reside in Canada and are epidemiologically unlinked. Despite presence of baseline resistance-associated substitutions within the GT8 virus of all 4 patients (NS3: V36L, Q80K/R; NS5A: Q30S, Y93S), all patients achieved a sustained virologic response; 2 treated with sofosbuvir/velpatasvir/voxilaprevir for 8 weeks, 1 with sofosbuvir/ledipasvir plus ribavirin for 24 weeks and 1 with sofosbuvir plus daclatasvir for 12 weeks. CONCLUSIONS: The discovery of a novel HCV GT8 confirms the circulation of this newly identified lineage in the human population.
引用
- Borgia SM, Hedskog C, Parhy B, et al. Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. J Infect Dis. 2018. PMID: 29982508. doi:10.1093/infdis/jiy401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。